Kiyatec Announces New Clinical Evidence in High Grade Glioma Accepted for Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) 2022

Clinical application of a functional 3D ex vivo test to predict therapeutic response in patients with high grade glioma: a progression-free survival analysis

Kiyatec, a leader in functional precision oncology, announced new clinical evidence of its proprietary ex vivo 3D cell culture technology use in high-grade glioma will be presented at ASCO 2022. As a first-time ASCO presenter and exhibitor, Kiyatec will present its Clinical Services and Drug Development Services capabilities at ASCO’s first-ever Innovation Hub at kiosk #IH01. The ASCO meeting will be held in Chicago June 3-7, 2022.

In this updated cohort of 42 patients with high grade glioma, 3D Predict™ Glioma prospectively predicted patient response to standard of care temozolomide (TMZ), regardless of MGMT methylation status. In a subgroup analysis of the 23 MGMT unmethylated patients, test-predicted responders had a relative median progression-free survival advantage of 5.9 months versus test-predicted non-responders (p = 0.0018). This data provides additional evidence of 3D Predict™ Glioma predictivity and its potential to provide additional information for glioma patient treatment options including clinical trial enrollment, alternative therapies indicated for use in glioma or combination therapy with TMZ.

Kiyatec Chief Executive Officer Matthew Gevaert, PhD, said, “This enhanced cohort adds to our body of clinical evidence demonstrating the predictive insights 3D Predict™ Glioma can provide to neuro-oncologists planning treatment for glioblastoma patients. With it, we’ve advanced our mission is to disrupt cancer care by accurately predicting patient-specific response and non-response before treatment begins.”

High grade gliomas, including glioblastoma, are among the most aggressive brain cancers, with patients exhibiting highly variable treatment responses in both newly diagnosed and recurrent disease. TMZ with radiation therapy is the guideline-directed standard of care in the newly-diagnosed setting, which has remained relatively unchanged for over 15 years despite variable patient responses.

Kiyatec’s ex vivo KIYA-Predict™ pre-clinical platform and 3D Predict™ clinical assays are leading the functional precision oncology space with published, clinically-correlated evidence to prospectively predict glioma patient therapeutic response prior to initiation of therapy.

Clinical application of a functional 3D ex vivo test to predict therapeutic response in patients with HGG: A progression-free survival analysis

Central Nervous System Tumors

Sunday June 5 8:00 – 11:00am

Abstract ID 2031

About Kiyatec

Kiyatec is a functional precision oncology company that measures the response of each patient’s live cancer cells to inform oncologists’ treatment selection decisions. The company’s Clinical Services offers clinical testing for high-grade glioma, and is developing assays for use in ovarian, breast, non-small cell lung cancers, and rare tumors in its CLIA-certified lab. The company’s Drug Development Services works in partnership with leading biopharmaceutical companies to unlock response dynamics for their pre-clinical investigational drug candidates across the majority of solid tumor types. For more information, visit www.kiyatec.com and connect with us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005564/en/